Loading patent…
AssigneeIovance Biotherapeutics, Inc.
InventorsAnand Veerapathran, Aishwary Gokuldass, Brian Rabinovich, Michael T. Lotze
Estimating the term…
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.
(canceled)
An isolated artificial antigen presenting cell (aAPC) comprising a K562 myeloid cell, an MOLM14 cell, or an EM-3 cell, wherein the aAPC is stably transduced with one or more viral vectors comprising a nucleic acid encoding a 4-1BBL polypeptide, wherein the aAPC expresses the 4-1BBL polypeptide on its surface, wherein the aAPC is capable of expanding a tumor infiltrating lymphocyte (TIL), when co-cultured with the aAPC, into a population of TILs, wherein the aAPC preferentially increases CD8+ TILs, and wherein
An isolated artificial antigen presenting cell (aAPC) comprising a K562 myeloid cell endogenously expressing CD58, wherein the aAPC expresses, via stable transduction with one or more viral vectors, 4-1BBL and IL-21, wherein the aAPC expresses the 4-1BBL on its surface, wherein the aAPC is capable of expanding a tumor infiltrating lymphocyte (TIL), when co-cultured with the TIL, into a population of TILs, and wherein the aAPC preferentially increases CD8+ TILs.
Dependencies are inferred from the claim text.